ValuEngine Upgrades Rosetta Genomics (ROSG) to Sell
Separately, Barrington Research cut Rosetta Genomics from an "outperform" rating to a "market perform" rating in a research report on Monday, December 18th. Rosetta Genomics traded down $0.06 during trading on Friday, reaching $0.50.
from Biotech News
0 Comments